Cookie Settings

We use cookies to optimize our website. These include cookies that are necessary for the operation of the site, as well as those that are only used for anonymous statistic. You can decide for yourself which categories you want to allow. Further information can be found in our data privacy protection .


These cookies are necessary to run the core functionalities of this website and cannot be disabled.

Name Webedition CMS
Purpose This cookie is required by the CMS (Content Management System) Webedition for the system to function correctly. Typically, this cookie is deleted when the browser is closed.
Name econda
Purpose Session cookie emos_jcsid for the web analysis software econda. This runs in the “anonymized measurement” mode. There is no personal reference. As soon as the user leaves the site, tracking is ended and all data in the browser are automatically deleted.

These cookies help us understand how visitors interact with our website by collecting and analyzing information anonymously. Depending on the tool, one or more cookies are set by the provider.

Name econda
Purpose Statistics
External media

Content from external media platforms is blocked by default. If cookies from external media are accepted, access to this content no longer requires manual consent.

Name YouTube
Purpose Show YouTube content
Name Twitter
Purpose activate Twitter Feeds

One million € funding for the development of norovirus therapeutics

No. 27c2 | 08/08/2016

Grant Hansman, head of the CHS Research Group noroviruses, has raised funding under the BMBF funding program "Validation of the Technological and Social Innovation Potential of Scientific Research" in the amount of € 1,164,000. Hansman will develop new antiviral Nanobodies in the project, which can be used as a norovirus therapeutics and diagnostics.

Electron micrograph of norovirus virus-like particles (VLPs) and a cartoon representation of a nanobody, termed Nano-85 (orange). Nano-85 binds to the VLPs and causes the VLPs to disassemble.
© Dr. Grant Hansman, DKFZ

Human noroviruses are the dominant etiological agent of outbreaks of acute gastroenteritis and a major cause of sporadic infections. Noroviruses are highly infectious and less than 100 viral particles are sufficient for an infection. Despite the discovery of norovirus more than 40 years ago, there are still no approved vaccines, antivirals, or treatments. Human noroviruses are genetically and antigenically distinct.

Similar to the influenza virus, the norovirus genome is constantly evolving and novel strains emerge every other year that can lead to new epidemics and even pandemics. Human noroviruses cannot be grown robustly in cell culture, which has hampered the development of vaccines and antivirals. The first clinical studies of a norovirus vaccine were only recently, however the results were met with uncertainties, i.e., lower than expected coverage, little cross protection from other strains, and lack of long term-immunity. Nevertheless, the symptoms of gastroenteritis appeared to be slightly reduced in those immunized.

Grant Hansman's group aims at developing antivirals against human norovirus that can reduce infections, treat symptoms, or both. For this purpose, Hansman and colleagues have produced a library of "Nanobodies" that are directed against norovirus particles in order to identify ones that might inhibit norovirus infections.

Nanobodies are antibody fragments, which are composed of a monomeric, variable domain of an antibody. Hansman and colleagues identified one Nanobody (termed Nano-85) that is able to bind to antigenically distinct noroviruses with nanomolar affinities. They also found that Nano-85 binds to a highly conserved region on the virus particle and the binding interaction causes the particles to disassemble. The researchers believe that this region likely plays a central role in the stability of the particles.

The purpose of this proposal is to provide evidence that the binding of Nano-85 to this unique target region inhibits norovirus infections, since the structural integrity of particles is likely needed for replication and infection. As part of this project Hansman and colleagues will further develop Nano-85 and other Nanobodies to bind to murine norovirus with higher affinities. Overall, they will use a multidisciplinary approach to validate the interactions using bioinformatics, X-ray crystallography, molecular biology techniques, and cell culture.

The underlying concept is that Nanobodies directed against the highly conserved region(s) of the viral particles will disrupt infection, thereby reducing virus replication. Hansman will determine these effects, for the first time, in the murine norovirus cell culture system with the ultimate aim of developing antivirals for preclinical trials.

With more than 3,000 employees, the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) is Germany’s largest biomedical research institute. DKFZ scientists identify cancer risk factors, investigate how cancer progresses and develop new cancer prevention strategies. They are also developing new methods to diagnose tumors more precisely and treat cancer patients more successfully. The DKFZ's Cancer Information Service (KID) provides patients, interested citizens and experts with individual answers to questions relating to cancer.

To transfer promising approaches from cancer research to the clinic and thus improve the prognosis of cancer patients, the DKFZ cooperates with excellent research institutions and university hospitals throughout Germany:

  • National Center for Tumor Diseases (NCT, 6 sites)
  • German Cancer Consortium (DKTK, 8 sites)
  • Hopp Children's Cancer Center (KiTZ) Heidelberg
  • Helmholtz Institute for Translational Oncology (HI-TRON Mainz) - A Helmholtz Institute of the DKFZ
  • DKFZ-Hector Cancer Institute at the University Medical Center Mannheim
  • National Cancer Prevention Center (jointly with German Cancer Aid)
The DKFZ is 90 percent financed by the Federal Ministry of Education and Research and 10 percent by the state of Baden-Württemberg. The DKFZ is a member of the Helmholtz Association of German Research Centers.


Subscribe to our RSS-Feed.

to top
powered by webEdition CMS